Atyr PHARMA (NASDAQ:ATYR) & MiNK Therapeutics (NASDAQ:INKT) Head to Head Review

Atyr PHARMA (NASDAQ:ATYR) and MiNK Therapeutics (NASDAQ:INKT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Analyst Ratings

This is a summary of recent recommendations for Atyr PHARMA and MiNK Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atyr PHARMA	0	0	6	1	3.14
MiNK Therapeutics	0	0	2	0	3.00

Atyr PHARMA presently has a consensus target price of $18.60, suggesting a potential upside of 436.02%. MiNK Therapeutics has a consensus target price of $37.50, suggesting a potential upside of 398.01%. Given Atyr PHARMA’s stronger consensus rating and higher probable upside, equities research analysts clearly believe Atyr PHARMA is more favorable than MiNK Therapeutics.

Volatility & Risk

Atyr PHARMA has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, MiNK Therapeutics has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500.

Valuation & Earnings

This table compares Atyr PHARMA and MiNK Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atyr PHARMA	$235,000.00	1,312.09	-$50.39 million	($0.87)	-3.99
MiNK Therapeutics	N/A	N/A	-$22.46 million	($2.92)	-2.58

MiNK Therapeutics has lower revenue, but higher earnings than Atyr PHARMA. Atyr PHARMA is trading at a lower price-to-earnings ratio than MiNK Therapeutics, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

61.7% of Atyr PHARMA shares are owned by institutional investors. Comparatively, 2.9% of MiNK Therapeutics shares are owned by institutional investors. 3.7% of Atyr PHARMA shares are owned by insiders. Comparatively, 20.6% of MiNK Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Atyr PHARMA and MiNK Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Atyr PHARMA	N/A	-79.44%	-59.16%
MiNK Therapeutics	N/A	N/A	-189.14%

Summary

Atyr PHARMA beats MiNK Therapeutics on 9 of the 13 factors compared between the two stocks.

About Atyr PHARMA

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

About MiNK Therapeutics

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.